Kamada (KMDA) has released an update.
Kamada Ltd., a global biopharmaceutical company, is set to announce its financial results for the third quarter and nine months ending September 30, 2024, on November 13, 2024. Known for its expertise in specialty plasma-derived products, Kamada continues to expand its product portfolio and market presence across over 30 countries. Investors are keenly watching Kamada’s progress, especially with its ongoing Phase 3 trial for an inhaled treatment for AAT deficiency.
For further insights into KMDA stock, check out TipRanks’ Stock Analysis page.
